OncoMatch/Clinical Trials/NCT04389086
Induction Chemotherapy for Locally Recurrent Rectal Cancer
Is NCT04389086 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Combination drug for recurrent rectal cancer.
Treatment: Combination drug — This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: DPYD homozygous deficiency
Known homozygous DPD deficiency
Performance status
WHO 0–1
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify